Quarterly report pursuant to Section 13 or 15(d)

Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details)

v3.24.3
Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details) - USD ($)
3 Months Ended 9 Months Ended
Apr. 12, 2024
Sep. 30, 2024
Jun. 30, 2024
Sep. 30, 2024
Sep. 23, 2024
Revenue          
Revenue in the period       $ (161,007,000)  
Strategic Collaboration and License Agreement          
Revenue          
Amount of cumulative catch-up adjustment at the date of the termination $ 101,348,000        
Aggregate remaining transaction price that had not yet been recognized as revenue $ 146,301,000        
Revenue in the period     $ (20,741,000)    
Payments of milestone         $ 12,500,000
Amount of deferred income that was subsequently recognised as revenue due to the contract ending   $ 25,298,000   25,298,000  
Payments of additional milestone   12,500,000   $ 12,500,000  
Total revenue recognised on termination of the contract   $ 37,798,000